An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging

被引:15
|
作者
Wanet, Marie [1 ]
Delor, Antoine [2 ]
Hanin, Francois-Xavier [3 ]
Ghaye, Benoit [4 ]
Van Maanen, Aline [5 ]
Remouchamps, Vincent [6 ]
Clermont, Christian [6 ]
Goossens, Samuel [1 ]
Lee, John Aldo [1 ]
Janssens, Guillaume [1 ]
Bol, Anne [1 ]
Geets, Xavier [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Mol Imaging Radiotherapy & Oncol MIRO, Ave Hippocrate,54 Bte B1-54-07, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Radiat Oncol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Dept Nucl Med, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium
[5] Clin Univ St Luc, Stat Support Unit, Canc Ctr, B-1200 Brussels, Belgium
[6] CHU UCL Namur, Dept Radiat Oncol, Clin & Maternite St Elisabeth Namur, B-5000 Namur, Belgium
关键词
Non-small cell lung cancer; Dose escalation; FDG-PET imaging; Intensity modulated radiotherapy; Toxicity; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; NORMAL TISSUE CONSTRAINTS; THERAPY ONCOLOGY GROUP; PHASE-II; CONCURRENT CHEMORADIATION; THORACIC RADIOTHERAPY; RESPONSE EVALUATION; NSCLC PATIENTS; SOLID TUMORS;
D O I
10.1007/s00066-017-1168-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. Patients and methods total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes). The fraction dose was increased within the individual PET-based PTV (PTVPET) using intensity modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) until the predefined organ-at-risk (OAR) threshold was reached. Tumor response was assessed during follow-up by means of repeat FDG-PET/computed tomography. Acute and late toxicity were recorded and classified according to the CTCAE criteria (Version 4.0). Local progression-free survival was determined using the Kaplan-Meier method. Results The average dose to PTVPET reached 89.17 Gy for peripheral and 75 Gy for central tumors. After a median follow-up period of 29 months, seven patients were still alive, while six had died (four due to distant progression, two due to grade 5 toxicity). Local progression was seen in two patients in association with further recurrences. One and 2-year local progression free survival rates were 76.9% and 52.8%, respectively. Three cases of acute grade 3 esophagitis were seen. Two patients with central tumors developed late toxicity and died due to severe hemoptysis. Conclusion hese results suggest that a non-uniform and individualized dose escalation based on FDG-PET in IMRT delivery is feasible. The doses reached were higher in patients with peripheral compared to central tumors. This strategy enables good local control to be achieved at acceptable toxicity rates. However, dose escalation in centrally located tumors with direct invasion of mediastinal organs must be performed with great caution in order to avoid severe late toxicity.
引用
收藏
页码:812 / 822
页数:11
相关论文
共 50 条
  • [21] Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods in the thoracic and extrathoracic staging of non-small cell lung cancer
    Antonio Rodríguez Fernández
    Manuel Gómez Río
    José Manuel Llamas Elvira
    Abel Sánchez-Palencia Ramos
    María Bellón Guardia
    Carlos Ramos Font
    Pablo Torné Poyatos
    Vicente Pedraza Muriel
    Clinical and Translational Oncology, 2007, 9 : 32 - 39
  • [22] FDG-PET and Chemotherapy for Successful Diagnosis and Treatment of Cardiac Metastasis from Non-Small Cell Lung Cancer
    Sato, Ryo
    Ichiyasu, Hidenori
    Saeki, Sho
    Sakata, Shinya
    Sasaki, Ji-ichirou
    Fujii, Kazuhiko
    Saita, Naoki
    Kohrogi, Hirotsugu
    INTERNAL MEDICINE, 2012, 51 (14) : 1909 - 1912
  • [23] FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology
    Ryu, JS
    Choi, NC
    Fischman, AJ
    Lynch, TJ
    Mathisen, DJ
    LUNG CANCER, 2002, 35 (02) : 179 - 187
  • [24] Evaluation of efficacy and clinical impact of FDG-PET on patients with potentially resectable non-small cell lung cancer
    Dorado, I. Borrego
    Garcia, C. Lopez
    Albertino, R. Vazquez
    Canamaque, A. Ginel
    Cortes, E. Barrot
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2007, 26 (06): : 335 - 344
  • [25] Diagnosis efficacy of structural (CT) and functional (FDG-PET) imaging methods in the thoracic and extrathoracic staging of non-small cell lung cancer
    Rodriguez Fernandez, Antonio
    Gomez Rio, Manuel
    Llamas Elvira, Jose Manuel
    Sanchez-Palencia Ramos, Abel
    Bellon Guardia, Maria
    Ramos Font, Carlos
    Torne Poyatos, Pablo
    Pedraza Muriel, Vicente
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2007, 9 (01) : 32 - 39
  • [26] A Clinical Study of Shrinking Field Radiation Therapy Based on 18F-FDG PET/CT for Stage III Non-Small Cell Lung Cancer
    Ding, Xiuping
    Li, Hongsheng
    Wang, Zhongtang
    Huang, Wei
    Li, Baosheng
    Zang, Rukun
    Sun, Hongfu
    Yi, Yan
    TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2013, 12 (03) : 251 - 257
  • [27] Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial
    Westover, Kenneth D.
    Loo, Billy W., Jr.
    Gerber, David E.
    Iyengar, Puneeth
    Choy, Hak
    Diehn, Maximilian
    Hughes, Randy
    Schiller, Joan
    Dowell, Jonathan
    Wardak, Zabi
    Sher, David
    Christie, Alana
    Xie, Xian-Jin
    Corona, Irma
    Sharma, Akanksha
    Wadsworth, Margaret E.
    Timmerman, Robert
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2015, 93 (01): : 72 - 81
  • [28] Predicting Radiation Esophagitis Using 18F-FDG PET During Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer
    Mehmood, Qurrat
    Sun, Alexander
    Becker, Nathan
    Higgins, Jane
    Marshall, Andrea
    Le, Lisa W.
    Vines, Douglass C.
    McCloskey, Paula
    Ford, Victoria
    Clarke, Katy
    Yap, Mei
    Bezjak, Andrea
    Bissonnette, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : 213 - 221
  • [29] Lung and Heart Dose Variability During Radiation Therapy of Non-Small Cell Lung Cancer
    Jan, Nuzhat
    Guy, Christopher
    Reshko, Leonid B.
    Hugo, Geoffrey D.
    Weiss, Elisabeth
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2017, 98 (03): : 683 - 690
  • [30] Accelerated dose escalation with proton beam therapy for non-small cell lung cancer
    Gomez, Daniel R.
    Chang, Joe Y.
    JOURNAL OF THORACIC DISEASE, 2014, 6 (04) : 348 - 355